InMed completes Mentari merger and renames itself Mentari Therapeutics, with PACAP migraine antibody in Phase 1
InMed Pharmaceuticals closed its two-step merger with Mentari Therapeutics on 6 November and adopted the Mentari name; lead anti-PACAP antibody MT-001 is in a New Zealand Phase 1 trial.
InMed Pharmaceuticals Inc. has completed its two-step merger with Mentari Therapeutics and changed its name to Mentari Therapeutics, Inc. The transaction closed on 6 November 2026, according to the management's discussion and analysis (MD&A) filed alongside the company's Form 8-K.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): InMed Pharmaceuticals Inc. ↗
Article written by VigiEye from the official source (InMed Pharmaceuticals Inc.). Claims are the company's own. AI-assisted; check the source before acting.